echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's "Remazolam" 3rd indication enters "under approval"

    Hengrui Medicine's "Remazolam" 3rd indication enters "under approval"

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 8, Hengrui Medicine's application for the new indication of "Remazolam Tosylate for Injection" entered the approval stage and is expected to be approved in the near future


    Remazolam is a short-acting GABAa receptor agonist designed by GSK company and developed by PaionAG company.


    Due to the unstable free base of remazolam, Paion developed it as a besylate of remazolam


    Remazolam tosylate is used by Hengrui Pharmaceuticals in the salt-type screening process.


    The research and development history of Hengrui Remazolam Tosylate (Image source: corporate website)

    In March 2018, the market application for the indication of remazolam tosylate for gastroscopy sedation was accepted by CDE and was subsequently included in the priority review range


    On June 24, 2020, the second indication of remazolam tosylate for injection was approved for marketing for colonoscopy for diagnosis and treatment of sedation


    Subsequently, in December 2020, February and May 2021, Hengrui submitted three applications for the marketing of remazolam for new indications of category 2.


    Remazolam besylate project details (Insight)

    From: Insight database (http://db.


    Insight database shows that Hengrui has initiated 4 phase III clinical trials for remazolam tosylate, all of which have been completed


    Phase II and Phase III clinical trials of remazolam tosylate (Insight)

    From: Insight database (http://db.


    In addition, remazolam tosylate has been approved for clinical applications for four other indications, namely, ICU mechanical ventilation sedation, and sedation before, during, and during non-intubation anesthesia operations


    In last year's medical insurance negotiations, remazolam tosylate did not enter the medical insurance through negotiations, and this year, this new drug will again be negotiated in 2021


    Not only remazolam tosylate, Hengrui will also seek to enter the medical insurance catalogue through negotiations with fluzoparil and trelopopag; apatinib and carrelizumab will participate this year with new indications Medical insurance negotiations


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.